MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Almaula, N.
Right arrow Articles by Sealfon, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Almaula, N.
Right arrow Articles by Sealfon, S. C.

Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5- hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus

N Almaula, BJ Ebersole, JA Ballesteros, H Weinstein and SC Sealfon

Fishberg Research Center in Neurobiology, Mount Sinai School of Medicine, New York, New York 10029, USA.

An important determinant of the neurobehavioral responses induced by a drug is its relative receptor selectivity. The molecular basis of ligand selectivity of hallucinogenic and nonhallucinogenic compounds of varying structural classes for the human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors was investigated with the use of reciprocal site- directed mutagenesis. Because these two closely related receptor subtypes differ in the amino acid present at position 5.46 (residues 242 and 222 in the sequences, respectively), the effects of corresponding substitutions in the 5-HT2A[S5.46(242)-->A] and 5- HT2C[A5.46(222)-->S] receptors were studied in tandem. By studying both receptors, the direct and indirect effects of mutations on affinity and selectivity can be distinguished. The ergolines studied, mesulergine (selective for the 5-HT2C receptor) and d-lysergic acid diethylamide (selective for the 5-HT2A receptor), reversed their relative affinity with mutations in each receptor, supporting a direct role of this locus in the selectivity of these ligands. However, interchange mutations in either receptor led to decreased or unchanged affinity for (+/-)-1- )(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and ketanserin, which have higher affinity for the 5-HT2A receptor, consistent with little contribution of this locus to the selectivity of these ligands. The indoleamines studied were affected differently by mutations in each receptor, suggesting that they bind differently to the two receptor subtypes. Mutation of this locus in the 5-HT2A receptor decreased the affinity of all indoleamines, whereas the interchange mutation of the 5- HT2C receptor did not affect indoleamine affinity. These results are consistent with a direct interaction between this side chain and indoleamines for the 5-HT2A receptor but not for the 5-HT2C receptor. Furthermore, this analysis shows that the higher affinity of 5-HT and tryptamine for the 5-HT2C receptor than for the 5-HT2A receptors is not due to the difference at this locus. The hallucinogens studied [d- lysergic acid diethylamide, psilocin, bufotenin, and (+/-)-1-(2,5- dimethoxy-4-iodophenyl)-2-aminopropane] fell into different classes in this analysis. For the classes of ligand studied, the side-chain difference at this position directly determines relative ligand selectivity only for ergolines and may contribute to the specific effects of hallucinogens in this class.

Volume 50, Issue 1, pp. 34-42, 07/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Neurosci.Home page
M. C. Clark, T. E. Dever, J. J. Dever, P. Xu, V. Rehder, M. A. Sosa, and D. J. Baro
Arthropod 5-HT2 Receptors: A Neurohormonal Receptor in Decapod Crustaceans That Displays Agonist Independent Activity Resulting from an Evolutionary Alteration to the DRY Motif
J. Neurosci., March 31, 2004; 24(13): 3421 - 3435.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
B. J. Ebersole, I. Visiers, H. Weinstein, and S. C. Sealfon
Molecular Basis of Partial Agonism: Orientation of Indoleamine Ligands in the Binding Pocket of the Human Serotonin 5-HT2A Receptor Determines Relative Efficacy
Mol. Pharmacol., January 1, 2003; 63(1): 36 - 43.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Manivet, B. Schneider, J. C. Smith, D.-S. Choi, L. Maroteaux, O. Kellermann, and J.-M. Launay
The Serotonin Binding Site of Human and Murine 5-HT2B Receptors. MOLECULAR MODELING AND SITE-DIRECTED MUTAGENESIS
J. Biol. Chem., May 3, 2002; 277(19): 17170 - 17178.
[Abstract] [Full Text] [PDF]


Home page
Protein Eng Des SelHome page
I. Visiers, S. A. Hassan, and H. Weinstein
Differences in conformational properties of the second intracellular loop (IL2) in 5HT2C receptors modified by RNA editing can account for G protein coupling efficiency
Protein Eng. Des. Sel., June 1, 2001; 14(6): 409 - 414.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
D. A. Shapiro, K. Kristiansen, W. K. Kroeze, and B. L. Roth
Differential Modes of Agonist Binding to 5-Hydroxytryptamine2A Serotonin Receptors Revealed by Mutation and Molecular Modeling of Conserved Residues in Transmembrane Region 5
Mol. Pharmacol., November 1, 2000; 58(5): 877 - 886.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
Z. H. Song, C.-A. Slowey, D. P. Hurst, and P. H. Reggio
The Difference between the CB1 and CB2 Cannabinoid Receptors at Position 5.46 Is Crucial for the Selectivity of WIN55212-2 for CB2
Mol. Pharmacol., October 1, 1999; 56(4): 834 - 840.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
K. A. Berg, S. Maayani, J. Goldfarb, C. Scaramellini, P. Leff, and W. P. Clarke
Effector Pathway-Dependent Relative Efficacy at Serotonin Type 2A and 2C Receptors: Evidence for Agonist-Directed Trafficking of Receptor Stimulus
Mol. Pharmacol., July 1, 1998; 54(1): 94 - 104.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
J. Ballesteros, S. Kitanovic, F. Guarnieri, P. Davies, B. J. Fromme, K. Konvicka, L. Chi, R. P. Millar, J. S. Davidson, H. Weinstein, et al.
Functional Microdomains in G-protein-coupled Receptors. THE CONSERVED ARGININE-CAGE MOTIF IN THE GONADOTROPIN-RELEASING HORMONE RECEPTOR
J. Biol. Chem., April 24, 1998; 273(17): 10445 - 10453.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
F. G. Boess, F. J. Monsma Jr., V. Meyer, C. Zwingelstein, and A. J. Sleight
Interaction of Tryptamine and Ergoline Compounds with Threonine 196 in the Ligand Binding Site of the 5-Hydroxytryptamine6 Receptor
Mol. Pharmacol., September 1, 1997; 52(3): 515 - 523.
[Abstract] [Full Text]


Home page
Endocr. Rev.Home page
S. C. Sealfon, H. Weinstein, and R. P. Millar
Molecular Mechanisms of Ligand Interaction with the Gonadotropin-Releasing Hormone Receptor
Endocr. Rev., April 1, 1997; 18(2): 180 - 205.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1996 by the American Society for Pharmacology and Experimental Therapeutics